Metastatic melanoma survivor Mike Potthoff shares why an immunotherapy clinical trial was the right treatment option for him after other options failed to keep the cancer in remission.
Jeff Deatsman didn’t know the human papillomavirus could cause tonsil cancer in men until he was diagnosed with the disease. He’s since become an advocate for the HPV vaccine, and had his own two sons vaccinated.
Throat cancer survivor Damion Smith had been covering stories about MD Anderson for years as a news photographer, so he already knew it provided world-class cancer care. But until he became a patient himself, he didn’t appreciate how much ‘caring’ went into it.
MD Anderson researchers identify metastatic cell types and mechanisms of drug resistance in triple-negative breast cancer, providing leads for improving breast cancer treatment.
An international alliance of melanoma researchers works to test proven therapies for metastatic disease in clinical trials before surgery for locally advanced melanoma.
Adela Justice, a senior librarian at The Learning Center at MD Anderson, can do more than help patients and caregivers learn more about cancer. She also can play the electric bass and has been a reserve deputy.
Some 23 years after her initial ocular melanoma diagnosis at age 19, Britta Fortson was diagnosed with stage IV ocular melanoma. She came to MD Anderson, where she's on an immunotherapy clinical trial.
An MD Anderson analysis of three clinical trials shows that the targeted therapy drug larotrectinib resulted in a 79% overall response rate in adult and pediatric patients with advanced cancers and NTRK gene fusions.
New brain metastases sequencing research suggests these lesions are not identical to the original tumors.
MD Anderson researchers perform the first large scale genomic analysis that reveals evolution from precancerous growths to lung cancer.